Motility, Parkinsonism, and Prolactin with Thiothixene and Thioridazine

Archives of General Psychiatry

Volumn 38, Issue 6, 1981, Pages 668-675

  Crowley, Thomas J ^a   Hydinger Macdonald, Marilyn ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; THIORIDAZINE; TIOTIXENE;

ADVERSE DRUG REACTION; CASE REPORT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG COMPARISON; DRUG THERAPY; EXTRAPYRAMIDAL SYMPTOM; MOTILITY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEDATION; THERAPY;

ADULT; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MALE; MIDDLE AGE; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PROLACTIN; SCHIZOPHRENIA; SUPPORT, U.S. GOV'T, P.H.S.; THIORIDAZINE; THIOTHIXENE;

EID: 0019411396     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1981.01780310068007     Document Type: Article

References (85)

1. Van Praag HM, Korf F: Importance of dopamine metabolism for clinical effects and side effects of neuroleptics. Am J Psychiatry 1976;133: 1171–1177.
2. Lidsky TI, Weinhold PM, Levine FM: Implications of basal ganglionic dysfunction for schizophrenia. Biol Psychiatry 1979;14: 3–12.
3. Matthysse S: Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed Proc 1974;32: 200–205.
4. McLean JR, Parker RB, Coughenour LL: Effect of antipsychotic and other classes of drugs on spontaneous locomotor activity and neurotoxicity in mice. Pharmacol Biochem Behav 1978;8: 97–99.
5. Buus Lassen J: Inhibition and potentiation of apomorphine-induced hypermotility in rats by neuroleptics. Eur J Pharmacol 1976;36: 385–393.
6. Heal DJ, Green AR, Boullin DJ, et al: Single and repeated administration of neuroleptic drugs to rats: Effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-dopa. Psychopharmacology 1976;49: 287–300.
7. Heal DJ, Green AR, Bloomfield MR, et al: Neuroleptic drugs block both the hyperactivity and the increase in caudate nucleus cyclic AMP concentration produced by the administration of tranylcypromine and L-dopa to rats. Psychopharmacology 1978;57: 193–197.
8. Pijnenburg AJJ, Honic WMM, Van Rossum JM: Inhibition of D-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 1975;41: 87–95.
9. Costall B, Naylor RJ, Cannon JG, et al: Differentiation of the dopamine mechanisms mediating stereotyped behavior and hyperactivity in the nucleus accumbens and caudate-putamen. J Pharm Pharmacol 1977;29: 337–342.
10. Costall B, Naylor RJ, Pinder RM: Characterization of the mechanism for hyperactivity induction from the nucleus accumbens by phenylethylamine derivatives. Psychopharmacology 1976;48: 225–231.
11. Pijnenberg AJJ, Honig WMM, Van Rossum JM: Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialamide-pretreated rats. Psychopharmacologia 1975;41: 175–180.
12. Ungerstedt U, Ljungberg T: Behavioral patterns related to dopamine neurotransmission: Effect of acute and chronic antipsychotic drugs, in Costa E, Gessa GL (eds): Advances in Biochemical Psychopharmacology. New York, Raven Press, 1977, pp 193–199.
13. Ljungberg T, Ungerstedt U: Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacology 1978;56: 239–247.
14. Crowley TJ, Jones RH, Hydinger-Macdonald MJ, et al: Everyother-day acetylmethadol disturbs circadian cycles of human motility. Psychopharmacology 1979;62: 151–155.
15. Crowley TJ, Hydinger-Macdonald MJ: Bedtime flurazepam and the human circadian rhythm of spontaneous motility. Psychopharmacology 1979;62: 157–161.
16. Colburn TR, Smith BM, Guarini JJ, et al: An ambulatory activity monitor with solid state memory. Biomed Sci Instrum 1976;12: 117–122.
17. Gardos G, Finnerty RJ, Cole JO: Thiothixene and trifluoperazine in a step system. Psychosomatics 1970;11: 36–40.
18. Jacobsen S: Psychotropic agents, in Detre TP, Jarecki HG (eds): Modern Psychiatric Treatment. Philadelphia, JB Lippincott Co, 1971, pp 528–610.
19. Langer G, Sachar EJ, Halpern FS, et al: The prolactin response to neuroleptic drugs: A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 1977;45: 996–1002.
20. Hollister LE: Antipsychotic medications and the treatment of schizophrenia, in Barchas JD, Berger PA, Ciaranello RD, et al (eds): Psychopharmacology: From Theory to Practice. New York, Oxford University Press, 1977, pp 121–150.
21. Spitzer RL, Endicott J, Cohen GM: Psychiatric Status Schedule, ed 2. New York, New York State Psychiatric Institute, 1968.
22. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 1967;17: 427–442.
23. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962;10: 799–812.
24. Halberg R, Johnson EA, Nelson W, et al: Autorhythmometry procedures for physiologic self-measurements and their analysis. Physiol Teacher 1972;4: 1–11.
25. Twelfth International Conference Proceedings, International Society for Chronobiology. Milan, Italy, Il Ponte, 1977.
26. Downie NM, Heath RW: Basic Statistical Methods, ed 2. Hagerstown, Md, Harper & Row Publishers Inc, 1965.
27. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 2. Washington, DC, American Psychiatric Association, 1968.
28. Meltzer HY, Fang VS, Fessler R, et al: Neuroleptic-stimulated prolactin secretion in the rat as an animal model for biological psychiatry: I. Comparison with antipsychotic activity, in Hanin I, Usdin E (eds): Animal Models in Psychiatry and Neurology. New York, Pergamon Press, 1977, pp 443–445.
29. De Rivera JL, Lal S, Ettigi P, et al: Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 1976;5: 273–282.
30. Englehardt DM, Rosen B, Freedman N, et al: Phenothiazines in prevention of psychiatric hospitalization: II. Duration of treatment exposure. JAMA 1963;186: 981–983.
31. Hogarty GE, Ulrich RF: Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 1977;34: 297–301.
32. Zavodnick S: A pharmacological and theoretical comparison of high and low potency neuroleptics. J Clin Psychiatry 1978;39: 332–336.
33. Bunney WE, Wehr TR, Gillin JC, et al: The switch process in manic-depressive psychosis. Ann Intern Med 1977;87: 319–335.
34. Brown GL, Hunt RD, Ebert MH, et al: Plasma levels of D-amphetamine in hyperactive children. Psychopharmacology 1979;62: 133–140.
35. DiMascio A, Demirgian E: Study of the activating properties of thiothixene. Psychosomatics 1972;13: 105–108.
36. Overall JE, Hollister LE, Meyer F, et al: Imipramine and thioridazine in depressed and schizophrenic patients: Are there specific antidepressant drugs? JAMA 1964;189: 605–608.
37. Goldstein BJ, Banas FA: Clinical evaluation of thiothixene in the treatment of hospitalized depressed patients. Curr Ther Res 1968;10: 453–456.
38. Pennington VM: The antipsychotic and antidepressant power of thiothixene. Psychosomatics 1968;9: 346–348.
39. Overall JE, Hollister LE, Shelton J, et al: Broad-spectrum screening of psychotherapeutic drugs: Thiothixene as an antipsychotic and antidepressant. Clin Pharmacol Ther 1969;10: 36–43.
40. Haug JO: Kontrollerte kliniske forsok med thioridazin (Melleril) et nytt phenothiazinderivat. Tidsskr Nor Laegeforen 1959;6: 317–321.
41. Stabenau JR, Grinols DE: A double-blind comparison of thioridazine and chlorpromazine. Psychiatr Q 1964;38: 42–63.
42. Wright RLD, Kyne WP: A clinical and experimental comparison of four anti-schizophrenic drugs. Psychopharmacologia 1960;1: 437–439.
43. Hollister LE, MacDonald BF: Thioridazine (Mellaril) in psychiatric patients. Calif Med 1959;91: 274–277.
44. Remy M: Essai d'un nouveau derive de la phenothiazine, le Melleril, en clinique psychiatrique. Schweiz Med Wochenschr 1958;88: 1221–1225.
45. Schiele BC, Vestre ND, Stein KE: A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: A double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. J Clin Exp Psychopathol Q 1961;22: 151–162.
46. Bellville TP, Heistad GT, Schiele BC: A comparative study of thioridazine and carphenazine using sequential analysis. Psychopharmacologia 1963;4: 53–65.
47. Hollister LE, Traub L, Prusmack JJ: Use of thioridazine for intensive treatment of schizophrenics refractory to other tranquilizing drugs. J Neuropsychiatr 1960;1: 200–204.
48. Sandison RA, Whitelaw E, Currie JDC: Clinical trials with Melleril (TP21) in the treatment of schizophrenia. J Ment Sci 1960;106: 732–741.
49. Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins Co, 1969, p 96.
50. Sugerman AA: Studies with the thioxanthenes. Mod Probl Pharmacopsychiatry 1969;2: 80–84.
51. Bishop MP, Gallant DM, Steele CA: Extended trial of thiothixene in chronic psychotic patients. Psychiatr Dig 1968;29: 15–22.
52. Goldstein B, Weiner D, Banas F: Clinical evaluation of thiothixene in chronic ambulatory schizophrenic patients. Mod Probl Pharmacopsychiatry 1969;2: 45–52.
53. Hollister LE: Some human pharmacological studies of three psychotropic drugs: Thiothixene, molindone, and W-1867. J Clin Pharmacol 1968;8: 95–101.
54. Ban TA: Psychopharmacology of Thiothixene. New York, Raven Press, 1978.
55. Wolpert A, Sheppard C, Merlis S: Thiothixene, thioridazine, and placebo in male chronic schizophrenic patients. Clin Pharmacol Ther 1968;9: 456–464.
56. Gallant DM, Bishop MP, Timmons E, et al: Thiothixene (P-4657B): A controlled evaluation in chronic schizophrenic patients. Curr Ther Res 1966;8: 153–158.
57. Hardeman WJ, Bakker SJ: Double-blind comparative study of the effects of thiothixene and thioridazine in 20 chronic schizophrenic patients. Psychiatr Neurol Neurochir 1970;73: 1–7.
58. Bergling R, Mjorndal T, Oreland L, et al: Plasma levels and clinical effects of thioridazine and thiothixene. J Clin Pharmacol 1975;15: 178–186.
59. Gardos G, Cole JO: The dual action of thiothixene. Arch Gen Psychiatry 1973;29: 222–225.
60. Gardos G, Orzack MH, Finn G, et al: High and low dose thiothixene treatment in chronic schizophrenia. Dis Nerv Syst 1974;35: 53–58.
61. Hoehn MM, Crowley TJ, Rutledge CO: Dopamine correlates of neurologic and psychologic status in untreated parkinsonism. J Neurol Neurosurg Psychiatry 1976;39: 941–951.
62. Crowley TJ, Hoehn MM, Rutledge CO, et al: Dopamine excretion and vulnerability to drug-induced parkinsonism: Schizophrenic patients. Arch Gen Psychiatry 1978;35: 97–104.
63. Hobbs DC, Welch WM, Short MJ, et al: Pharmacokinetics of thiothixene in man. Clin Pharmacol Ther 1974;16: 473–478.
64. Ng CH, Crammer JL: Measurement of thioridazine in blood and urine. Br J Clin Pharmacol 1977;4: 173–183.
65. Muusze RG, Vanderheeren FAJ: Plasma levels and half lives of thioridazine and some of its metabolites: II. Low doses in older psychiatric patients. Eur J Clin Pharmacol 1977;11: 141–147.
66. Meltzer HY, Fang VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33: 279–286.
67. Gerlach J, Simmelsgaard H: Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology 1978;59: 105–112.
68. Crane GE: Persistence of neurological symptoms due to neuroleptic drugs. Am J Psychiatry 1971;127: 1407–1410.
69. Degkwitz R: Extrapyramidal motor disorders following long-term treatment with neuroleptic drugs, in Crane GE, Gardener L (eds): Psychotropic Drugs and Dysfunction of the Basal Ganglia, No. 1938. Public Health Service, 1969, pp 22–35.
70. Mettler FA, Crandell A: Relationship between parkinsonism and psychiatric disorder. J Nerv Ment Dis 1959;129: 551–563.
71. Beumont PJV, Corker CS, Friesen HG, et al: The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women. Br J Psychiatry 1974;124: 420–430.
72. Kolakowska T, Wiles DH, McNeilly AS, et al: Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients. Psychol Med 1975;5: 214–216.
73. Sachar EJ, Gruen PH, Altman N, et al: Prolactin responses to neuroleptic drugs: An approach to the study of brain dopamine blockade in humans, in Usdin E (ed): Neuroregulators and Psychiatric Disorders. New York, Oxford University Press, 1977, pp 242–249.
74. Gruen PH: The prolactin response in clinical psychiatry. Med Clin North Am 1978;62: 409–424.
75. Gruen PH, Sachar EJ, Langer G, et al: Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978;35: 108–116.
76. Wilson RG, Hamilton JR, Boyd WD, et al: The effect of long-term phenothiazine therapy on plasma prolactin. Br J Psychiatry 1975;127: 71–74.
77. Wode-Helgodt B, Eneroth P, Fyro B, et al: Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand 1977;56: 280–293.
78. Rubin RT, Hayes SE: Profiles of prolactin response to antipsychotic drugs: Some methodological considerations. Psychopharmacol Bull 1978;14: 9–11.
79. Nokin J, Vekemans M, l'Hermite M, et al: Circadian periodicity of serum prolactin concentration in man. Br Med J 1972;3: 561–562.
80. Parker DC, Rossman LG, Vanderlaan EF: Sleep-related, nyctohemeral, and briefly episodic variation in human plasma prolactin concentrations. J Clin Endocrinol Metab 1973;36: 1119–1127.
81. Sassin JF, Frantz AG, Kapen S, et al: The nocturnal rise of human prolactin is dependent on sleep. J Clin Endocrinol Metab 1973;37: 436–440.
82. Villablanca JR, Marcus RJ, Olmstead CE: Effects of caudate nuclei or frontal cortical ablations in cats: I. Neurology and gross behavior. Exp Neurol 1976;52: 389–420.
83. Villablanca JR, Marcus RJ, Olmstead CE: Effects of caudate nuclei or frontal cortex ablations in cats: II. Sleep-wakefulness, EEG, and motor activity. Exp Neurol 1976;53: 31–50.
84. Richter CP, Hines M: Increased spontaneous activity produced in monkeys by brain lesions. Brain 1938;61: 1–17.
85. Carlsson A: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135: 164–173.